Clinical Trial Update: Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM [Phase 3]

View source ↗

Summary

Phase 3 trial in children and adolescents evaluating linagliptin and empagliflozin (DINAMO) for type 2 diabetes is completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Empagliflozin (empagliflozin)
• Linagliptin (linagliptin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2024-02-23